These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19340042)

  • 1. Research review boards dogged by criticism.
    Ledford H
    Nature; 2009 Apr; 458(7238):557. PubMed ID: 19340042
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of escalating regulatory requirements on the conduct of clinical research.
    Gordon BG; Kessinger A; Mann SL; Prentice ED
    Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research involving children: regulations, review boards and reform.
    Gandhi R
    J Health Care Law Policy; 2005; 8(2):264-330. PubMed ID: 16471026
    [No Abstract]   [Full Text] [Related]  

  • 4. Data and safety monitoring boards: academic credit where credit is due?
    Armstrong PW; Califf RM
    JAMA; 2013 Oct; 310(15):1563-4. PubMed ID: 24129461
    [No Abstract]   [Full Text] [Related]  

  • 5. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making more sense of "minimal risk".
    Barnbaum D
    IRB; 2002; 24(3):10-3. PubMed ID: 12848183
    [No Abstract]   [Full Text] [Related]  

  • 8. Designing a data and safety monitoring plan.
    Slimmer L; Andersen B
    West J Nurs Res; 2004 Nov; 26(7):797-803. PubMed ID: 15466615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Playing safe and preserving integrity: making the FDA model work.
    Wittes J
    Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing the paradigm: new directions in federal oversight of human research.
    Koski G
    J Pediatr Gastroenterol Nutr; 2003; 37 Suppl 1():S2-6. PubMed ID: 14685070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 12. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees.
    ; ;
    Stat Med; 2006 May; 25(10):1639-45. PubMed ID: 16639775
    [No Abstract]   [Full Text] [Related]  

  • 13. The Global Forum for Bioethics in Research: report of a meeting.
    Loff B; Hofman K; Muthuswamy V
    Issues Med Ethics; 2001; 9(2):63-4. PubMed ID: 16334477
    [No Abstract]   [Full Text] [Related]  

  • 14. Data safety and monitoring boards for African clinical trials.
    Lang T; Chilengi R; Noor RA; Ogutu B; Todd JE; Kilama WL; Targett GA
    Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1189-94. PubMed ID: 18644610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Institutional review boards (IRBs) and working with adverse event reports.
    Maloney DM
    Hum Res Rep; 2005 Dec; 20(12):1-3. PubMed ID: 16607708
    [No Abstract]   [Full Text] [Related]  

  • 16. India tightens regulation of clinical trials to safeguard participants.
    Chatterjee P
    BMJ; 2013 Feb; 346():f1275. PubMed ID: 23440346
    [No Abstract]   [Full Text] [Related]  

  • 17. Data safety and monitoring boards.
    Wells RJ
    N Engl J Med; 2004 Jun; 350(23):2423;; author reply 2423. PubMed ID: 15175451
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ethics symposium. 2-3 April 2007, Paris, France. Foreword].
    Ahouanto M
    Bull Soc Pathol Exot; 2008 Apr; 101(2):75-6. PubMed ID: 18543696
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of the unblinded sponsor statistician.
    Snapinn S; Cook T; Shapiro D; Snavely D
    Stat Med; 2004 May; 23(10):1531-3. PubMed ID: 15122733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of good clinical practice to challenge tests.
    Bailey JE
    J Psychopharmacol; 2004 Mar; 18(1):16; author reply 18-9. PubMed ID: 15107178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.